• Qlife Holding’s third-quarter 2026 net loss narrowed 44% year over year to SEK 3.93 million.
• Revenue fell to none from SEK 65,000, while total cash flow turned negative at SEK 2.8 million.
• The company is entering a product-readiness phase with its pharmaceutical partner, backed by SEK 2.7 million in partner funding.
• Post-quarter milestones included U.S. patent clearance for core Egoo technology and ISO 13485 certification covering its at-home PHE blood-testing solution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.